Fennec Pharmaceuticals annual operating margin
2020
2022
2023
2024
2025
Fennec Pharmaceuticals's operating margin was −14.07% for fiscal 2025.
View full Fennec Pharmaceuticals company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −14.07% | −19.47 pp |
| 2024 | 2024-12-31 | 5.40% | +59.10 pp |
| 2023 | 2023-12-31 | −53.70% | +1223.24 pp |
| 2022 | 2022-12-31 | −1,276.94% | +9243.65 pp |
| 2020 | 2020-12-31 | −10,520.59% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 9.72% | +38.02 pp |
| Q1 2026 | 2026-03-31 | −0.79% | +8.45 pp |
| Q4 2025 | 2025-12-31 | −18.53% | −6.75 pp |
| Q3 2025 | 2025-09-30 | −1.52% | +73.07 pp |
| Q2 2025 | 2025-06-30 | −28.31% | +41.08 pp |
| Q1 2025 | 2025-03-31 | −9.23% | −63.39 pp |
| Q4 2024 | 2024-12-31 | −11.79% | +3.04 pp |
| Q3 2024 | 2024-09-30 | −74.59% | −58.98 pp |
| Q2 2024 | 2024-06-30 | −69.39% | +70.94 pp |
| Q1 2024 | 2024-03-31 | 54.16% | +368.41 pp |
| Q4 2023 | 2023-12-31 | −14.82% | +1953.41 pp |
| Q3 2023 | 2023-09-30 | −15.61% | — |
| Q2 2023 | 2023-06-30 | −140.33% | — |
| Q1 2023 | 2023-03-31 | −314.25% | — |
| Q4 2020 | 2020-12-31 | −1,968.24% | — |
Across the available reported history, Fennec Pharmaceuticals's operating margin decreased from 5.40% to −14.07%, a change of −19.47 percentage points. The latest reported quarter, Q2 2026, shows 9.72%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Fennec Pharmaceuticals filings at SEC.gov ↗